公司概覽
業務類別 Biotechnology
業務概覽 Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
公司地址 Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
電話號碼 +353 16347800
傳真號碼 +353 16347850
公司網頁 https://www.jazzpharmaceuticals.com
員工數量 2890
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Renee D. Gala President, Chief Executive Officer and Director 美元 1.00M 08/06/2026
Dr. Robert Iannone, M.D. Executive Vice President, Global Head of Research and Development and Chief Medical Officer 美元 793.08K 08/06/2026
Mr. Philip L. Johnson Executive Vice President and Chief Financial Officer 美元 741.35K 08/06/2026
Ms. Neena M. Patil Executive Vice President and Chief Legal Officer 美元 715.48K 08/06/2026
Ms. Patricia Carr Senior Vice President and Chief Accounting Officer -- 08/06/2026
Ms. Samantha Pearce Executive Vice President and Chief Commercial Officer 美元 695.67K 09/10/2026
Ms. Mary Elizabeth Henderson Senior Vice President, Technical Operations -- 08/06/2026
 
董事會成員
董事會 職務 更新日期
Mr. Bruce C. Cozadd Chairperson of the Board 08/06/2026
Mr. Patrick G. Enright, M.B.A. Independent Director 08/06/2026
Dr. Norbert G. Riedel,PhD Independent Director 08/06/2026
Dr. Ted W. Love, M.D. Independent Director 08/06/2026
Mr. Rick E. Winningham Lead Independent Director 08/06/2026
Ms. Heather Ann McSharry Independent Director 08/06/2026
Mr. Patrick Thomas Kennedy Independent Director 08/06/2026
Mr. Seamus C. Mulligan Independent Director 08/06/2026
Ms. Renee D. Gala President, Chief Executive Officer and Director 08/06/2026
Ms. Laura J. Hamill Independent Director 08/06/2026
Ms. Jennifer E. Cook Independent Director 08/06/2026
Dr. Mark D. Smith, M.D. Independent Director 08/06/2026
 
所屬ETF (更新日期: 14/11/2026 03:34)
代號 名稱 佔比% ▼ 持有日期
SPXXNuveen S&P 500 Dynamic Overwrite0.004%30/09/2026
MSMLiShares MSCI USA Small-Cap ETF0.004%30/10/2026
ITANSparkline Intangible Value ETF0.004%30/10/2026
SMDXIntech S&P Small-Mid Cap Divers Alp ETF0.004%30/10/2026
ACMGAmerican Century Mid Cap Gr Insgts ETF0.003%30/10/2026
MVVProShares Ultra MidCap4000.003%30/10/2026
GUSAGoldman Sachs MarketBeta US 1000 Eq ETF0.003%30/10/2026
ANGUSEI Ang Research Enh U.S. Lg Cp ETF0.003%30/10/2026
HELXFranklin Genomic Advancements ETF0.003%31/10/2026
OPTZOptimize Strategy Index ETF0.003%30/10/2026
CVRTCalamos Convertible Equity Alt ETF0.003%30/09/2026
MFUSPIMCO RAFI Dyn Multi-Factor US Eq ETF0.003%30/10/2026
QLVNorthern Trust US Quality Lw Volatil ETF0.003%30/10/2026
FNDBSchwab Fundamental U.S. Broad Market ETF0.003%31/10/2026
PAMCPacer Lunt MidCap Multi-Factor Alt ETF0.003%30/10/2026
TAXCambria Tax Aware ETF0.002%30/10/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.002%31/10/2026
IUSInvesco RAFI™ Strategic US ETF0.002%30/10/2026
VSLUApplied Finance Valuation LgCp ETF0.002%30/10/2026
JHMLJHancock Multifactor Large Cap ETF0.002%30/10/2026
  1    2    3    4    5    6    7   8    9    10    11  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.